Patents Represented by Attorney, Agent or Law Firm Nelsen L. Lentz
-
Patent number: 6515026Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to process for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: January 18, 2002Date of Patent: February 4, 2003Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6506746Abstract: The invention provides a method of treating a cognitive dysfunction comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b][1,5]benzodiazepine.Type: GrantFiled: November 25, 1997Date of Patent: January 14, 2003Assignee: Eli Lilly and CompanyInventor: Charles M Beasley, Jr.
-
Patent number: 6500865Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: January 23, 2001Date of Patent: December 31, 2002Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, Thomas John Bleisch, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6465453Abstract: The present invention provides compounds of formula I and a method of inhibiting the reuptake of serotonin, antagonizing the 5-HT1A receptor and antagonizing the 5-HT2A receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of formula I.Type: GrantFiled: November 28, 2000Date of Patent: October 15, 2002Assignee: Eli Lilly and CompanyInventors: Kenneth Lee Hauser, Larry Wayne Hertel, Yao-Chang Xu
-
Patent number: 6448396Abstract: The present invention provides a process of preparing a compound of the formula IV wherein: R1 and R2 are each individually -(C1-C6)alkyl, -(C1-C6)alkoxy or phenyl, R3 is H or -(C1-C6)alkyl, R6 is —NR7R8, morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl or piperazin-1-yl substituted with -(C1-C4)alkyl or and R7 and R8 are each individually hydrogen, -(C1-C6)alkyl, —(CH2)pOH, —(CH2)p-piperidyl, —(CH2)pS(C1-C6)alkyl, —(CH2)pO(C1-C6)alkyl where R9 is (C1-C6)alkyl; P is an integer from 1-3 both inclusive; q is 0 or 1; and t is 1 to 6 both inclusive; or a pharmaceutically acceptable salt, hydrate or optical isomer thereof, which is useful as a neuroprotective agent.Type: GrantFiled: September 23, 1998Date of Patent: September 10, 2002Assignee: Eli Lilly and CompanyInventors: Benjamin Alan Anderson, Lawrence Joseph Heinz, Jill Ann Panetta, Michael LeRoy Phillips, John Allan Rieck, III, John Robert Rizzo, John Kevin Shadle, David Lee Varie
-
Patent number: 6444665Abstract: The present invention provides a method for treating pain using an atypical antipsychotic compound.Type: GrantFiled: February 4, 2000Date of Patent: September 3, 2002Assignee: Eli Lilly and CompanyInventors: David R. Helton, Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman
-
Patent number: 6436964Abstract: The present invention provides the compounds of the following formula: Wherein the variables are as defined in the specification and a method for inhibiting the reuptake of seretonin, antagonizing the 5-HT1A receptor and antagonizing the 5-HT2A receptor which comprises administering to a subject in need of such treatment an effective amount of the compound of above formula.Type: GrantFiled: November 28, 2000Date of Patent: August 20, 2002Assignee: Eli Lilly and CompanyInventors: Larry Wayne Hertel, Daniel Timothy Kohlman, Sidney Xi Liang, David Taiwai Wong, Yao-Chang Xu
-
Patent number: 6432943Abstract: The invention provides a method for treating a sexual dysfunction comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine.Type: GrantFiled: September 28, 1998Date of Patent: August 13, 2002Assignee: Eli Lilly and CompanyInventor: Pierre Van Tran
-
Patent number: 6387954Abstract: The present invention provides certain alkenyl sulphonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: January 23, 2001Date of Patent: May 14, 2002Assignee: Eli Lilly and CompanyInventors: Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6380213Abstract: This invention relates to novel phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents.Type: GrantFiled: November 17, 2000Date of Patent: April 30, 2002Assignee: Eli Lilly and CompanyInventors: Jill Ann Panetta, John Kevin Shadle, Lawrence Joseph Heinz, Michael LeRoy Phillips, John Robert Rizzo, Benjamin Alan Anderson, John Allan Rieck, III, David Lee Varie
-
Patent number: 6362230Abstract: The present invention provides novel sulphonamide derivatives which are useful for potentiating glutamate receptor function in a mammal requiring treatment, processes for their preparation, and pharmaceutical compositions containing them.Type: GrantFiled: November 21, 2000Date of Patent: March 26, 2002Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, Paul Leslie Ornstein, Dennis Michael Zimmerman, Ana Maria Escribano
-
Patent number: 6358982Abstract: The present invention relates to the potentiation of glutamate receptor function using certain heterocyclyl sulphonamide derivatives. It also relates to novel heterocyclyl sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: January 23, 2001Date of Patent: March 19, 2002Assignee: Eli Lilly and CompanyInventors: Buddy Eugene Cantrell, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6358981Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: January 23, 2001Date of Patent: March 19, 2002Assignee: Eli Lilly and CompanyInventors: Macklin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6355655Abstract: The present invention relates to the potentiation of glutamate receptor function using certain heterocyclic sulphonamide derivatives. It also relates to novel heterocyclic sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: January 23, 2001Date of Patent: March 12, 2002Assignee: Eli Lilly and CompanyInventors: Ana Maria Escribano, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 6342498Abstract: Anylpiperazines of formula (1) useful as serotonin reuptake inhibitors and 5-HT1D&agr; receptor antagonists are disclosed herein: wherein R1 and R2 are each independently hydrogen, halo, —(C1-C6)alkyl or —(C1-C6)alkoxy; R3 is hydrogen or —(C1-C6)alkyl; Y is —CO— or —CH2—; Z is —NH—, —N(COR)— or —CH2— where R is —(C1-C6)alkyl or —(C3-C8)cycloalkyl; represents a double or single bond; n and m are an each independently integer from 1 to 3, both inclusive; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 31, 2000Date of Patent: January 29, 2002Assignee: Eli Lilly and CompanyInventors: Clint Duane Walker, David Taiwai Wong, Yao-Chang Xu
-
Patent number: 6329364Abstract: A physical form of (R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine having an X-ray powder diffraction pattern with d spacings at 12.78, 9.48, 8.99, 8.64, 8.23, 6.39, 6.27. 5.73, 4.01 and 3.96 Å. The compound is useful as an AMPA antagonist.Type: GrantFiled: March 28, 1995Date of Patent: December 11, 2001Assignee: Eli Lilly and CompanyInventor: Edward G. Groleau
-
Patent number: 6303816Abstract: Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R1—L—NHSO2R2 I in which R1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are atType: GrantFiled: October 18, 1999Date of Patent: October 16, 2001Assignee: Eli Lilly and CompanyInventors: Macklin B Arnold, Stephen R Baker, David Bleakman, Thomas J Bleisch, Buddy E Cantrell, Ana M Escribano, Ken Matsumoto, Tracey E McKennon, Paul L Ornstein, Richard L Simon, Edward C. R. Smith, Joseph P Tizzano, Hamideh Zarrinmayeh, Dennis M Zimmerman
-
Patent number: 6239135Abstract: A series of aryl piperazine compounds of the formula: or the pharmaceutically acceptable salts thereof, are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.Type: GrantFiled: December 9, 1998Date of Patent: May 29, 2001Assignee: Eli Lilly and CompanyInventors: Daniel Timothy Kohlman, Yao-Chang Xu
-
Patent number: 6172073Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.Type: GrantFiled: March 27, 1998Date of Patent: January 9, 2001Assignee: Eli Lilly and CompanyInventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
-
Patent number: 6169105Abstract: The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.Type: GrantFiled: November 25, 1996Date of Patent: January 2, 2001Assignee: Eli Lilly and CompanyInventors: David Taiwai Wong, Juan Ignacio Oguiza